NYSE:CBM - Cambrex Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$63.70 +0.25 (+0.39 %)
(As of 08/20/2018 10:25 AM ET)
Previous Close$63.85
Today's Range$63.45 - $64.05
52-Week Range$42.55 - $67.75
Volume10,954 shs
Average Volume344,500 shs
Market Capitalization$2.04 billion
P/E Ratio20.09
Dividend YieldN/A
Beta2.4
Cambrex logoCambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

Receive CBM News and Ratings via Email

Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNYSE:CBM
CUSIP13201110
Phone201-804-3000

Debt

Debt-to-Equity RatioN/A
Current Ratio5.23
Quick Ratio4.20

Price-To-Earnings

Trailing P/E Ratio20.09
Forward P/E RatioN/A
P/E Growth1.45

Sales & Book Value

Annual Sales$534.46 million
Price / Sales3.96
Cash Flow$4.3720 per share
Price / Cash14.57
Book Value$16.62 per share
Price / Book3.83

Profitability

EPS (Most Recent Fiscal Year)$3.17
Net Income$102.45 million
Net Margins20.75%
Return on Equity22.32%
Return on Assets16.44%

Miscellaneous

Employees1,228
Outstanding Shares33,260,000
Market Cap$2.04 billion

Cambrex (NYSE:CBM) Frequently Asked Questions

What is Cambrex's stock symbol?

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) issued its quarterly earnings data on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.69 by $0.05. The biotechnology company had revenue of $152.05 million for the quarter, compared to the consensus estimate of $132.78 million. Cambrex had a net margin of 20.75% and a return on equity of 22.32%. The company's quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.76 EPS. View Cambrex's Earnings History.

When is Cambrex's next earnings date?

Cambrex is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Cambrex.

What guidance has Cambrex issued on next quarter's earnings?

Cambrex updated its FY18 earnings guidance on Thursday, August, 2nd. The company provided EPS guidance of 2.91-3.14 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.85.

What price target have analysts set for CBM?

3 analysts have issued 1-year price objectives for Cambrex's shares. Their predictions range from $60.00 to $60.00. On average, they expect Cambrex's stock price to reach $60.00 in the next twelve months. This suggests that the stock has a possible downside of 5.8%. View Analyst Price Targets for Cambrex.

What is the consensus analysts' recommendation for Cambrex?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cambrex.

Who are some of Cambrex's key competitors?

Who are Cambrex's key executives?

Cambrex's management team includes the folowing people:
  • Mr. Steven M. Klosk, Pres, CEO & Director (Age 61)
  • Mr. Tom G. Vadaketh, Exec. VP & CFO (Age 55)
  • Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 52)
  • Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 40)
  • Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy (Age 52)

Has Cambrex been receiving favorable news coverage?

Press coverage about CBM stock has trended somewhat positive on Monday, according to Accern Sentiment. The research firm rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cambrex earned a media and rumor sentiment score of 0.21 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 46.23 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Cambrex.

Who are Cambrex's major shareholders?

Cambrex's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.90%), Bank of New York Mellon Corp (4.47%), Dimensional Fund Advisors LP (4.27%), American Capital Management Inc. (2.19%), Boston Partners (2.12%) and Brown Advisory Inc. (1.98%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh and Steven M Klosk. View Institutional Ownership Trends for Cambrex.

Which major investors are selling Cambrex stock?

CBM stock was sold by a variety of institutional investors in the last quarter, including Brown Advisory Inc., Eqis Capital Management Inc., Granite Investment Partners LLC, US Bancorp DE, Connor Clark & Lunn Investment Management Ltd., Peregrine Capital Management LLC, Royce & Associates LP and King Luther Capital Management Corp. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh and Steven M Klosk. View Insider Buying and Selling for Cambrex.

Which major investors are buying Cambrex stock?

CBM stock was acquired by a variety of institutional investors in the last quarter, including Investment Counselors of Maryland LLC, BlackRock Inc., Wells Fargo & Company MN, Acadian Asset Management LLC, FMR LLC, Rice Hall James & Associates LLC, Cambiar Investors LLC and Millennium Management LLC. View Insider Buying and Selling for Cambrex.

How do I buy shares of Cambrex?

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cambrex's stock price today?

One share of CBM stock can currently be purchased for approximately $63.70.

How big of a company is Cambrex?

Cambrex has a market capitalization of $2.04 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.17 on an earnings per share basis. Cambrex employs 1,228 workers across the globe.

How can I contact Cambrex?

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]


MarketBeat Community Rating for Cambrex (NYSE CBM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  185 (Vote Outperform)
Underperform Votes:  171 (Vote Underperform)
Total Votes:  356
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel